99 related articles for article (PubMed ID: 22160602)
1. Validation of three BRCA1/2 mutation-carrier probability models Myriad, BRCAPRO and BOADICEA in a population-based series of 183 German families.
Schneegans SM; Rosenberger A; Engel U; Sander M; Emons G; Shoukier M
Fam Cancer; 2012 Jun; 11(2):181-8. PubMed ID: 22160602
[TBL] [Abstract][Full Text] [Related]
2. Clinical software development for the Web: lessons learned from the BOADICEA project.
Cunningham AP; Antoniou AC; Easton DF
BMC Med Inform Decis Mak; 2012 Apr; 12():30. PubMed ID: 22490389
[TBL] [Abstract][Full Text] [Related]
3. Efficient computation of the joint probability of multiple inherited risk alleles from pedigree data.
Madsen T; Braun D; Peng G; Parmigiani G; Trippa L
Genet Epidemiol; 2018 Sep; 42(6):528-538. PubMed ID: 29943416
[TBL] [Abstract][Full Text] [Related]
4. Use of the BOADICEA Web Application in clinical practice: appraisals by clinicians from various countries.
Brédart A; Kop JL; Antoniou AC; Cunningham AP; De Pauw A; Tischkowitz M; Ehrencrona H; Dolbeault S; Robieux L; Rhiem K; Easton DF; Devilee P; Stoppa-Lyonnet D; Schmutlzer R
Fam Cancer; 2018 Jan; 17(1):31-41. PubMed ID: 28623477
[TBL] [Abstract][Full Text] [Related]
5. Prospective Evaluation over 15 Years of Six Breast Cancer Risk Models.
Li SX; Milne RL; Nguyen-Dumont T; English DR; Giles GG; Southey MC; Antoniou AC; Lee A; Winship I; Hopper JL; Terry MB; MacInnis RJ
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680343
[TBL] [Abstract][Full Text] [Related]
6. Combining Breast Cancer Risk Prediction Models.
Guan Z; Huang T; McCarthy AM; Hughes K; Semine A; Uno H; Trippa L; Parmigiani G; Braun D
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831433
[TBL] [Abstract][Full Text] [Related]
7. Frailty Models for Familial Risk with Application to Breast Cancer.
Gorfine M; Hsu L; Parmigiani G
J Am Stat Assoc; 2013 Dec; 108(504):1205-1215. PubMed ID: 24678132
[TBL] [Abstract][Full Text] [Related]
8. Mutations as Levy flights.
Leon DA; Gonzalez A
Sci Rep; 2021 May; 11(1):9889. PubMed ID: 33972566
[TBL] [Abstract][Full Text] [Related]
9. Author Correction: Validation of the BOADICEA model for predicting the likelihood of carrying pathogenic variants in eight breast and ovarian cancer susceptibility genes.
Møller NB; Boonen DS; Feldner ES; Hao Q; Larsen M; Lænkholm AV; Borg Å; Kvist A; Törngren T; Jensen UB; Boonen SE; Thomassen M; Terkelsen T
Sci Rep; 2023 Sep; 13(1):15294. PubMed ID: 37714994
[No Abstract] [Full Text] [Related]
10. Guidelines for splicing analysis in molecular diagnosis derived from a set of 327 combined in silico/in vitro studies on BRCA1 and BRCA2 variants.
Houdayer C; Caux-Moncoutier V; Krieger S; Barrois M; Bonnet F; Bourdon V; Bronner M; Buisson M; Coulet F; Gaildrat P; Lefol C; Léone M; Mazoyer S; Muller D; Remenieras A; Révillion F; Rouleau E; Sokolowska J; Vert JP; Lidereau R; Soubrier F; Sobol H; Sevenet N; Bressac-de Paillerets B; Hardouin A; Tosi M; Sinilnikova OM; Stoppa-Lyonnet D
Hum Mutat; 2012 Aug; 33(8):1228-38. PubMed ID: 22505045
[TBL] [Abstract][Full Text] [Related]
11. Germline variation in cancer-susceptibility genes in a healthy, ancestrally diverse cohort: implications for individual genome sequencing.
Bodian DL; McCutcheon JN; Kothiyal P; Huddleston KC; Iyer RK; Vockley JG; Niederhuber JE
PLoS One; 2014; 9(4):e94554. PubMed ID: 24728327
[TBL] [Abstract][Full Text] [Related]
12. A high-throughput functional complementation assay for classification of BRCA1 missense variants.
Bouwman P; van der Gulden H; van der Heijden I; Drost R; Klijn CN; Prasetyanti P; Pieterse M; Wientjens E; Seibler J; Hogervorst FB; Jonkers J
Cancer Discov; 2013 Oct; 3(10):1142-55. PubMed ID: 23867111
[TBL] [Abstract][Full Text] [Related]
13. Secondary variants in individuals undergoing exome sequencing: screening of 572 individuals identifies high-penetrance mutations in cancer-susceptibility genes.
Johnston JJ; Rubinstein WS; Facio FM; Ng D; Singh LN; Teer JK; Mullikin JC; Biesecker LG
Am J Hum Genet; 2012 Jul; 91(1):97-108. PubMed ID: 22703879
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status.
Cunningham JM; Cicek MS; Larson NB; Davila J; Wang C; Larson MC; Song H; Dicks EM; Harrington P; Wick M; Winterhoff BJ; Hamidi H; Konecny GE; Chien J; Bibikova M; Fan JB; Kalli KR; Lindor NM; Fridley BL; Pharoah PP; Goode EL
Sci Rep; 2014 Feb; 4():4026. PubMed ID: 24504028
[TBL] [Abstract][Full Text] [Related]
15. Pathogenicity evaluation of BRCA1 and BRCA2 unclassified variants identified in Portuguese breast/ovarian cancer families.
Santos C; Peixoto A; Rocha P; Pinto P; Bizarro S; Pinheiro M; Pinto C; Henrique R; Teixeira MR
J Mol Diagn; 2014 May; 16(3):324-34. PubMed ID: 24607278
[TBL] [Abstract][Full Text] [Related]
16. Mutation analysis of BRCA1, BRCA2, PALB2 and BRD7 in a hospital-based series of German patients with triple-negative breast cancer.
Pern F; Bogdanova N; Schürmann P; Lin M; Ay A; Länger F; Hillemanns P; Christiansen H; Park-Simon TW; Dörk T
PLoS One; 2012; 7(10):e47993. PubMed ID: 23110154
[TBL] [Abstract][Full Text] [Related]
17. BRCA1 sequence variations in 160 individuals referred to a breast/ovarian family cancer clinic. Institut Curie Breast Cancer Group.
Stoppa-Lyonnet D; Laurent-Puig P; Essioux L; Pagès S; Ithier G; Ligot L; Fourquet A; Salmon RJ; Clough KB; Pouillart P; Bonaïti-Pellié C; Thomas G
Am J Hum Genet; 1997 May; 60(5):1021-30. PubMed ID: 9150149
[TBL] [Abstract][Full Text] [Related]
18. A high incidence of BRCA1 mutations in 20 breast-ovarian cancer families.
Serova O; Montagna M; Torchard D; Narod SA; Tonin P; Sylla B; Lynch HT; Feunteun J; Lenoir GM
Am J Hum Genet; 1996 Jan; 58(1):42-51. PubMed ID: 8554067
[TBL] [Abstract][Full Text] [Related]
19. Functional assays for analysis of variants of uncertain significance in BRCA2.
Guidugli L; Carreira A; Caputo SM; Ehlen A; Galli A; Monteiro AN; Neuhausen SL; Hansen TV; Couch FJ; Vreeswijk MP;
Hum Mutat; 2014 Feb; 35(2):151-64. PubMed ID: 24323938
[TBL] [Abstract][Full Text] [Related]
20. Analysis of 30 putative BRCA1 splicing mutations in hereditary breast and ovarian cancer families identifies exonic splice site mutations that escape in silico prediction.
Wappenschmidt B; Becker AA; Hauke J; Weber U; Engert S; Köhler J; Kast K; Arnold N; Rhiem K; Hahnen E; Meindl A; Schmutzler RK
PLoS One; 2012; 7(12):e50800. PubMed ID: 23239986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
